|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
For instance, mutations in the <i>isocitrate dehydrogenase 1 (IDH1)</i> gene, which occurs in a subgroup of glioma, correlate with risk of VTE, with low incidence in patients with presence of an <i>IDH1</i> mutation compared with those with <i>IDH1</i> wild-type status.
|
31041803 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Ivosidenib (AG-120) is a targeted mutant IDH1 inhibitor under evaluation in a phase 1 dose escalation and expansion study of IDH1-mutant advanced solid tumors including cholangiocarcinoma, chondrosarcoma, and glioma.
|
31028664 |
2020 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Glioma grading can be differentiated and IDH1 mutational status can be predicted using IVIM.
|
31014573 |
2019 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Increasing researchers have been involved in the study of glioma cell metabolism reprogramming since the significance of IDH1 was confirmed in glioma.
|
30978442 |
2019 |
|
Glioma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In contrast, IDH1 wt expression is upregulated in all glioma grades (concentration >0.1) compared to control brain tissue (0.007 ± 0.0016).
|
30943868 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Recent DNA methylation analyses revealed a small group of IDH mutant diffuse gliomas exhibiting decreased DNA hypermethylation resulting in substantial unfavorable prognosis comparable to glioblastoma.
|
30937703 |
2019 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
T1+Gad performed best for IDH typing of glioblastoma (sensitivity 91.9%, specificity 100%, AUC 0.945) and ADC for non-Gadolinium-enhancing gliomas (sensitivity 85.7%, specificity 78.4%, AUC 0.877).
|
30927935 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Arterial Spin Labeling for Glioma Grade Discrimination: Correlations with IDH1 Genotype and 1p/19q Status.
|
30878893 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
All those results support the translational potential of strategies targeting gliomas carrying IDH1 mutations.
|
30857299 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
One hundred and two individuals with IDH1/2 mutant or 1p/19q co-deleted glioma were genotyped and linked to the UPDB.
|
30823903 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MRI texture analysis could be used as a new noninvasive method for identification of gliomas with IDH1 mutation.
|
30777207 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this study, using our mouse model and primary patient-derived glioma cultures with IDH1 mutations, we investigated the function of IDH1<sup>R132H</sup> in the context of TP53 and ATRX loss.
|
30760578 |
2019 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
<b>Results</b>: We found that PD-L2 expression level was significantly upregulated in higher grade glioma and IDH wild-type glioma.
|
30713802 |
2019 |
|
Glioma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Moreover, MEOX2 expression was associated with IDH1/2 wildtype molecular subtype and was significantly correlated with overall survival of all gliomas and, more interestingly, in lower grade glioma.
|
30659268 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In 1 case, an IDH1 R132H-mutant glioma was misdiagnosed as a demyelinating condition by frozen section histology during the intraoperative consultation, and no resection was performed pending the final pathology report.
|
30611146 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<sup>18</sup>F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma.
|
30607877 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our research provides valuable insights into the tissue metabolism of human IDH1 mutant glioma and unravels new lipid-related targets.
|
30596429 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The mini-column method enables rapid identification of 2-HG, providing a promising strategy for intraoperative diagnosis of IDH1-mutated gliomas in the future.
|
30573870 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
rLTL was measured by qPCR in a Swedish population-based glioma case-control cohort (421 cases and 671 controls). rLTL was related to glioma risk and health parameters associated with asthma and allergy, as well as molecular events in glioma including IDH1 mutation, 1p/19q co-deletion, and EGFR amplification.
|
30560391 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutation of the isocitrate dehydrogenase (IDH) gene and co-deletion on chromosome 1p/19q is becoming increasingly relevant for the evaluation of clinical outcome in glioma.
|
30529899 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These data support the possibility of a functional tricarboxylic acid cycle that runs in reductive manner, as a probable mechanism of action of bevacizumab in IDH1 mutated gliomas and propose a new target pathway for effective treatment of malignant gliomas.
|
30511933 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We hypothesize that the primary cell pool isolated from LGG tumor contains a heterogeneous population consisting tumor cells at various stages of tumor progression including cells with early genetic lesions if any prior to acquisition of IDH1 mutation.
|
30460631 |
2019 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
<sup>1</sup> H-MRS enables non-invasive detection of 2-hydroxyglutarate (2-HG), an oncometabolite accumulating in gliomas carrying mutations in the isocitrate dehydrogenase (IDH) genes.
|
30457203 |
2019 |
|
Glioma
|
0.700 |
Biomarker
|
disease |
BEFREE |
We observed that IDH1<sup>R132H</sup> was highly suppressive of subcutaneous tumor growth driven by platelet-derived growth factor B (PDGFB), but IDH1<sup>R132H</sup> tumor growth and glioma penetrance were virtually indistinguishable from those of IDH1-wildtype tumors in orthotopic models.
|
30416682 |
2018 |
|
Glioma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Using the combination, the diagnostic sensitivity and specificity for IDH1 mutated gliomas were 93.3% and 88.9%, respectively.
|
30414094 |
2019 |